GlassScriptPhysician profile
Judith Irabor
NPI 1033797162
$8,573.54
in general payments reported to CMS, 2019-2025
26 companies · $1,214 in 2025
The $1,214 reported for 2025 was more than what 84% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $133 · 2022: $2,101 · 2023: $2,473 · 2024: $2,652 · 2025: $1,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,339.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,324.42 | 2022-2025 | Lybalvi, Aristada |
| Abbvie INC. | $1,100.46 | 2022-2025 | |
| Corium, LLC | $1,064.31 | 2021-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,052.73 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $817.01 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Tris Pharma INC | $647.59 | 2022-2025 | Dyanavel Xr, Onyda Xr |
| Lundbeck LLC | $592.42 | 2021-2025 | Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $565.87 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $305.47 | 2022-2025 | Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $231.70 | 2021-2024 | Ingrezza |
| Neos Therapeutics, LP | $163.72 | 2021-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Janssen Pharmaceuticals, INC | $159.40 | 2023-2025 | Spravato, Invega Trinza, Invega |
| Ironshore Pharmaceuticals INC. | $132.43 | 2022-2024 | Jornay Pm |
| Noven Therapeutics, LLC | $118.90 | 2022-2025 | Secuado, Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $49.09 | 2022-2024 | Trintellix |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $37.68 | 2024 | Cobenfy |
| Indivior INC. | $36.22 | 2024 | Perseris |
| Axsome Therapeutics, INC. | $32.07 | 2022-2023 | Auvelity |
| Biogen, INC. | $22.17 | 2024 | |
| Vanda Pharmaceuticals INC. | $20.19 | 2022 | |
| Almatica Pharma LLC | $19.64 | 2023 | Loreev Xr |
| Eisai INC. | $18.93 | 2022 | |
| Bausch Health US, LLC | $17.35 | 2025 | Aplenzin |
| Supernus Pharmaceuticals, INC. | $15.65 | 2023 | Qelbree |
| Avanir Pharmaceuticals, INC. | $14.13 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.99 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Irabor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.